This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 | I82.0 — Budd-Chiari syndrome |
| Special Copayment Reduction | V173 |
| Synonyms | None |
| Inheritance pattern | Mostly acquired; associated with hereditary thrombophilia (JAK2 V617F, Factor V Leiden, etc.) |
| OMIM | Not applicable (acquired vascular occlusion syndrome) |
| Prevalence | About 1–2 per million (Western data); higher proportion of inferior vena cava lesion type in Asia |
| Age at onset | Mainly ages 20–50; any age possible |
| C. Adult onset | Likelihood of first onset in adulthood very high — Budd-Chiari syndrome occurs almost exclusively in adults, and pediatric onset is rare. Adult thrombophilic conditions (myeloproliferative neoplasms, antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria, etc.) are the main causes. |
| Main symptoms | Abdominal pain, ascites, hepatomegaly, liver failure, lower extremity edema |
| Diagnostic criteria | Imaging confirmation of hepatic vein or inferior vena cava obstruction (Doppler ultrasound, CT, MRI) |
| Treatment | Anticoagulation, TIPS/DIPS, angioplasty, liver transplantation |
Budd-Chiari syndrome (BCS) is a rare vascular disease in which hepatic venous outflow is blocked by obstruction of the hepatic veins or inferior vena cava. The name of this syndrome derives from the names of two pioneering clinicians. The British physician George Budd (1808–1882) first systematically described the triad of hepatomegaly, ascites, and lower extremity edema due to hepatic vein thrombosis in his 1845 book On Diseases of the Liver. Based on autopsy findings at the time, he argued that hepatic vein obstruction was the direct cause of ascites, but he did not understand the underlying cause of thrombosis.
The Austrian pathologist Hans Chiari (1851–1916) analyzed three autopsy cases in 1899, described thrombotic obliteration of hepatic veins more precisely, and established it as an independent pathological entity. Chiari used the term "obliterating endophlebitis of the hepatic veins," and this description became the foundation of modern histopathological diagnostic criteria. Subsequently, combining the work of the two researchers, the name "Budd-Chiari syndrome" became established in the medical literature from the early 20th century.
Until the mid-20th century, this disease was recognized as a fatal condition with very high mortality, and with no specific treatment the prognosis was extremely poor. In the 1950s–60s, surgical portosystemic shunts were introduced, making ascites control and prolonged survival possible in some patients. In the 1970s–80s, with advances in angiography, membranous obstruction of the inferior vena cava (MOVC) was identified as a distinctive subtype in Asia and Africa. Cases reported from Japan, Korea, China, and India were dominated by membranous lesions, unlike the thrombotic form in the West, highlighting regional differences in pathophysiology.
From the 1980s, as molecular biological understanding of thrombophilia deepened, the role of underlying hematologic diseases in BCS patients began to be studied systematically. In the 1990s, myeloproliferative neoplasms (MPN) were identified as the most common cause of BCS, with particular attention to polycythemia vera and essential thrombocythemia. The discovery in 2005 of the JAK2 V617F mutation as a molecular marker of MPN brought a revolutionary change to BCS diagnosis as well. This mutation is detected in about 40–50% of BCS patients and has become an essential item in the evaluation algorithm for patients with BCS of unknown cause.
Therapeutically, the introduction of the transjugular intrahepatic portosystemic shunt (TIPS) in the 1990s was an important turning point, replacing surgical shunts. TIPS is an interventional radiology procedure that creates an artificial intrahepatic channel between the portal and hepatic veins to lower portal pressure, and because it can bypass occluded hepatic veins, it became a key means of treating BCS. In 2007, the direct intrahepatic portosystemic shunt (DIPS) was developed, making treatment possible even in patients in whom TIPS is anatomically difficult. Since the 2010s, a stepwise treatment strategy of anticoagulation-TIPS-liver transplantation has been established in international guidelines.
The causes of Budd-Chiari syndrome can be broadly divided into thrombotic and non-thrombotic causes. In most cases (about 80%), one or more thrombophilic conditions are identified, and multiple causes coexist in as many as 25–46%. The proportion of 'idiopathic' BCS, in which no single cause is clearly identified, was previously reported to be up to 25% in the West, but it has fallen greatly now that molecular tests such as JAK2 V617F testing are routine.
Myeloproliferative neoplasms (MPN) are the most common single cause of BCS, diagnosed in 40–50% of patients. They include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In these diseases, thrombotic risk is markedly increased by complex mechanisms such as overproduction of red cells·platelets, platelet dysfunction, and vascular endothelial cell activation. The JAK2 V617F mutation is found in more than 95% of MPN and can cause BCS even without clinically evident increases in blood counts, which is understood under the concept of "occult MPN."
Paroxysmal nocturnal hemoglobinuria (PNH) is an important cause observed in 10–20% of BCS patients. In PNH, deficiency of GPI-anchored proteins (CD55, CD59) results in complement-mediated red cell hemolysis, and in this process platelet activation and vascular endothelial injury are promoted, so thrombi form at atypical sites (hepatic veins, portal vein, cerebral veins). About 7–10% of PNH patients experience BCS at some point in life, and conversely, PNH screening (flow cytometry) is recommended in all BCS patients.
Antiphospholipid syndrome (APS) accounts for 5–15% of BCS. Lupus anticoagulant, anticardiolipin antibody, and anti-β2-glycoprotein I antibody cause arterial·venous thrombosis and recurrent miscarriage, and often occur together with autoimmune diseases such as systemic lupus erythematosus (SLE). Hereditary thrombophilias include the Factor V Leiden mutation (about 25%), the prothrombin G20210A mutation (about 5–10%), and protein C·protein S·antithrombin deficiency, with large differences in prevalence between Western and Asian patient groups.
Non-thrombotic causes include compression or direct invasion of the hepatic veins or inferior vena cava. Hepatocellular carcinoma (HCC), renal cell carcinoma, adrenal tumors, and liver metastases can cause BCS by compressing vessels or forming tumor thrombi. Hydatid cysts, liver abscesses, and amebic liver abscesses are also rare causes. In Asia, membranous obstruction of the inferior vena cava (MOVC) is an important subtype, characterized by a membrane forming in the upper inferior vena cava due to a congenital malformation or fibrosis after chronic inflammation. Pregnancy, oral contraceptives, and drugs such as dalazonide are also known risk factors.
Budd-Chiari syndrome itself is not a single-gene disease and does not follow Mendelian inheritance. However, several hereditary thrombophilias closely associated with the development of BCS have a clear molecular genetic basis. When evaluating BCS patients, genetic testing plays a key role in identifying the cause and in family history counseling.
The JAK2 V617F mutation is the most studied molecular marker in BCS patients. Janus kinase 2 (JAK2) is a cytoplasmic tyrosine kinase that mediates signal transduction of hematopoietic growth factor receptors such as erythropoietin (EPO), thrombopoietin (TPO), and granulocyte colony-stimulating factor (G-CSF). The somatic mutation in which valine (Val) at position 617 of JAK2 is replaced by phenylalanine (Phe) (JAK2 V617F) constitutively activates JAK2, causing growth factor-independent proliferation of hematopoietic progenitors. As a result, along with overproduction of red cells·platelets·granulocytes, platelet hyperactivation and increased interaction with vascular endothelial cells greatly raise thrombotic risk. JAK2 V617F is detected in 40–50% of BCS patients, and in some, "occult MPN" is diagnosed, in which only the mutation is identified without clinically evident polycythemia.
The Factor V Leiden (FVL) mutation is an autosomal dominant thrombophilia first described in 1994 at Leiden University in the Netherlands, in which arginine at position 506 of coagulation factor V is replaced by glutamine (c.1691G>A, p.Arg506Gln), inhibiting inactivation of FVa by activated protein C (APC). Due to this so-called "APC resistance," thrombotic risk increases 3–8-fold in heterozygotes and 50–80-fold in homozygotes. FVL is found in about 25% of Western BCS patients, but its frequency is low in Asian patients. The prothrombin G20210A mutation, a variant in the 3' untranslated region of prothrombin (Factor II) mRNA, also raises blood prothrombin levels and increases thrombotic risk 2–4-fold, and is found in 5–10% of BCS patients.
Protein C, protein S, and antithrombin deficiencies are each inherited as autosomal dominant traits (complete deficiency is autosomal recessive), and reductions in these natural anticoagulants markedly increase thrombotic risk. Protein C deficiency is caused by variants in the PROC gene, protein S deficiency by the PROS1 gene, and antithrombin deficiency by the SERPINC1 gene. The prevalence of each of these deficiencies in BCS patients is around 5–15%, but during acute liver failure, hepatic synthesis decreases, so it may be difficult to determine whether a deficiency is congenital.
The gene associated with PNH is PIG-A (phosphatidylinositol glycan class A), located on the short arm of the X chromosome (Xp22.2). Somatic PIG-A mutations inhibit GPI biosynthesis in hematopoietic stem cells, resulting in loss of expression of GPI-linked complement regulatory proteins (CD55, CD59). As genetic predispositions associated with APS, immunogenetic factors such as HLA-DR4 and HLA-DQ8 and TLR gene polymorphisms are being studied, but no clear single-gene cause has yet been identified.
Budd-Chiari syndrome is a rare disease worldwide, with an estimated prevalence in the West of about 1–2 per million and an annual incidence of 0.2–0.8 per million. These figures are higher than in the past due to improved diagnostic techniques and increased awareness, but misdiagnosis and diagnostic delay are still common. Accurate epidemiological data on the situation in Korea are lacking, but according to Health Insurance Review & Assessment Service (HIRA) data, several hundred patients are registered annually, and the diagnosis rate has recently been gradually increasing.
A female predominance (F:M ≈ 1.5–2:1) is reported in the West, related to pregnancy, oral contraceptive use, and the female predominance of autoimmune diseases. Age of onset is concentrated in adulthood, mainly ages 20–50, and pediatric onset is rare at less than 10% of the total. Unlike in adults, pediatric BCS is relatively more often caused by congenital anatomical malformations, abdominal trauma, and bacterial phlebitis than by thrombophilia.
Distinct regional clinical differences exist. In Asia (Japan, China, Korea, India) and Africa, membranous obstruction of the inferior vena cava (MOVC) or inferior vena cava thrombosis accounts for a substantial portion of BCS causes, whereas in the West hepatic vein thrombosis predominates. There are also reports that inferior vena cava lesions account for 40–60% of all BCS in China and India. This difference may be related to genetic background (FVL mutation is rare in Asia, and the frequency of JAK2 V617F differs), the prevalence of infections (typhoid, amebiasis), and drinking water contamination, but the exact cause is unknown.
Looking at the distribution by underlying cause, in large Western cohort studies (EUROSTAR, EN-Vie), MPN accounted for about 40–50%, prothrombin mutation about 5–10%, FVL about 25%, APS 5–15%, and PNH 10–20%. Multiple causes coexist in as many as 25–46% of all cases, so in BCS patients additional thrombophilia evaluation must be completed even after a single cause is identified. The recurrence rate of BCS after liver transplantation is 10–20%, occurring when the underlying cause was not sufficiently treated before transplantation or when autoimmune disease reactivates after discontinuation of immunosuppressants.
In Korea, it is registered and managed under Special Copayment Reduction code V173, and under the 2019 rare disease registration criteria, when the clinical·imaging diagnosis is confirmed, medical cost support can be received on condition of renewal every 5 years. The number of TIPS procedures at Korean medical institutions has steadily increased since the 2010s, and a multidisciplinary approach (hematology-gastroenterology-interventional radiology-liver transplant surgery) is becoming established, centered on large tertiary hospitals in Seoul.
The core pathophysiology of Budd-Chiari syndrome lies in hepatic venous outflow obstruction (HVOO). When intrahepatic blood flow becomes congested due to obstruction of the hepatic veins (right, middle, left hepatic vein) or of the inferior vena cava where the hepatic veins join, a chain reaction of hepatic congestion, hepatocyte ischemia, portal hypertension, ascites, and liver failure begins.
In the normal liver, blood entering through the hepatic artery (about 25%) and portal vein (about 75%) passes through the hepatic sinusoids and drains into the hepatic veins. When the hepatic veins are obstructed, hydrostatic pressure in the sinusoids rises sharply, which increases plasma filtration into the perisinusoidal space (Disse's space), excessively increasing hepatic lymph production. When lymph exceeding the capacity of the lymphatics on the liver surface leaks into the peritoneal cavity, ascites forms. Portal pressure also rises, resulting in splenic congestion, splenomegaly, esophageal·gastric varices, hemorrhoids, and dilation of abdominal wall collateral vessels.
Hepatocyte ischemia begins mainly in zone 3 (the centrilobular zone). Zone 3 hepatocytes around the hepatic veins have the most vulnerable oxygen supply and are the first to be damaged by congestive ischemia. In acute BCS, centrilobular necrosis occurs and ALT/AST rise sharply. With chronic progression, it develops through centrilobular fibrosis into a form resembling "reverse cardiac cirrhosis." In this process, hepatic stellate cells are activated and secrete excessive collagen, and as fibrosis progresses toward the portal tracts, it shows a distinctive histological pattern distinguishable from typical cirrhosis.
As a compensatory response to portal hypertension, intrahepatic·extrahepatic collateral vessels develop. Because the caudate lobe drains directly into the inferior vena cava through separate accessory hepatic veins, compensatory hypertrophy of the caudate lobe when the hepatic veins are obstructed is a characteristic imaging finding of BCS. This caudate lobe hypertrophy is clearly seen on CT or MRI and serves as a diagnostic clue for BCS. On the other hand, the caudate lobe hypertrophy can externally compress the inferior vena cava, causing secondary inferior vena cava stenosis.
Whether the clinical course is acute, subacute, or chronic is determined by the speed and extent of obstruction and the degree of collateral development. When the three main hepatic veins are occluded simultaneously and abruptly, dramatic fulminant hepatic failure can occur. When one or two hepatic veins are occluded gradually, some compensation occurs through collateral development, and in some cases it manifests only as ascites·splenomegaly·mild hepatic dysfunction. When cirrhosis develops in chronic BCS, the risks of portal hypertension complications (variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis) and hepatocellular carcinoma (HCC) increase markedly.
The clinical symptoms of Budd-Chiari syndrome vary according to the mode of onset (acute/subacute/chronic) and the site·extent of obstruction. Traditionally, abdominal pain, ascites, and hepatomegaly are called the "classic triad," but all three appear together in less than about 20% of cases. In many patients, ascites appears alone or the disease presents with nonspecific symptoms of chronic liver disease, so diagnosis is commonly delayed.
Abdominal pain is the most common initial symptom of acute BCS, occurring in 50–80% of patients. The pain is mainly located in the right upper quadrant or epigastrium and arises from stretching of Glisson's capsule due to hepatic congestion. With abrupt onset, severe abdominal pain may be accompanied by nausea, vomiting, and fever, and it is sometimes mistaken for an acute abdomen. In patients with a chronic course, it may appear mildly as only abdominal discomfort or bloating.
Ascites occurs in 80–90% of BCS patients and is the most common clinical manifestation. The ascites is high-protein (exudative) ascites due to hepatic congestion, and the serum-ascites albumin gradient (SAAG) is often 1.1 g/dL or more. Ascites may increase rapidly, causing abdominal distension, dyspnea, and difficulty walking. Refractory ascites that responds poorly to diuretics is a characteristic finding of BCS, and in this case the possibility of HVOO must be considered.
Jaundice occurs in acute or subacute BCS due to hepatocellular dysfunction and is an indicator of severe liver failure. In chronic BCS, jaundice may be mild or absent initially but may appear as cirrhosis progresses. Lower extremity edema is particularly prominent when there is an inferior vena cava lesion and appears as symmetrical pitting edema of both lower extremities. With inferior vena cava obstruction, severe lower extremity varicose veins and abdominal wall venous dilation (a caput medusae-like pattern) may be present.
Fatigue, weight loss, and anorexia are nonspecific systemic symptoms common in chronic BCS. Esophageal and gastric variceal bleeding is a serious complication of portal hypertension, presenting as hematemesis or melena, and is a life-threatening emergency. Hepatic encephalopathy occurs with chronic hepatic dysfunction and portosystemic shunting, presenting as confusion, memory impairment, sleep disturbance, and tremor. Spontaneous bacterial peritonitis (SBP) is a complication due to infection of ascites, presenting as fever, abdominal pain, and worsening ascites, and early antibiotic treatment is essential.
The characteristic signs on physical examination of patients with Budd-Chiari syndrome overlap with those of other chronic liver diseases, but several specific findings can clinically strongly suggest BCS. A systematic abdominal examination is particularly important.
Hepatomegaly is the most common physical sign, observed in more than 70% of BCS patients. The liver is firm and tender on palpation, and examination may be difficult due to ascites. Characteristically, the caudate lobe becomes enlarged and may be palpated as a firm mass in the central epigastrium or left upper quadrant. This caudate lobe hypertrophy is also clearly seen on CT/MRI and is known as a finding that strongly suggests BCS.
Abdominal distension due to ascites is clearly seen on inspection, and on examination shifting dullness and fluid wave are positive. With massive ascites, bowel sounds are decreased on auscultation, and periumbilical veins may be dilated. Abdominal wall venous dilation is a sign of portal hypertension or inferior vena cava obstruction, and checking the direction of blood flow is important. Upward flow (above the umbilicus) suggests inferior vena cava obstruction, and downward or lateral flow suggests portal hypertension.
Splenomegaly results from portal hypertension and is identified by left subcostal palpation. With severe splenomegaly, hypersplenism may cause thrombocytopenia, anemia, and leukopenia. When the spleen is difficult to palpate due to large ascites, it is confirmed by ultrasound. With jaundice, yellowing of the sclera and skin, dark urine, and gray stools may be observed.
Lower extremity edema is prominent with inferior vena cava lesions and appears as pitting edema of both lower extremities. Particularly in patients with membranous obstruction of the inferior vena cava, common in India and Asia, findings of chronic venous insufficiency with severe lower extremity varicose veins, skin pigmentation, and skin ulcers may appear. General signs of chronic liver disease such as spider angioma, palmar erythema, and leukonychia may also be observed in patients with chronic BCS.
In fulminant BCS, jaundice, signs of hepatic encephalopathy (flapping tremor, decreased consciousness), and bleeding tendency due to coagulopathy (bruising, petechiae) may appear rapidly. When hepatorenal syndrome is present, oliguria and findings of decreased renal function appear. With variceal bleeding, hypotension, tachycardia, pallor, and hematemesis or melena are observed.
Because Budd-Chiari syndrome is a rare disease, population screening of the general population is not performed. However, screening and early diagnosis strategies for groups at high risk of BCS can greatly improve prognosis. It is particularly important to include BCS in the differential diagnosis in patients with ascites, hepatomegaly, or abnormal liver function of unknown cause.
In radiological screening, abdominal ultrasound is the first test performed. Doppler ultrasonography can evaluate blood flow in the hepatic veins and inferior vena cava in real time and is used as the screening and first-line diagnostic tool for BCS. In normal hepatic veins, a triphasic waveform synchronized with the heartbeat is observed, whereas in BCS, flow is reduced, reversed (reversed flow), or absent. Stenosis or thrombus at the hepatic vein-inferior vena cava junction, thrombus within the inferior vena cava, caudate lobe hypertrophy, and ascites can be identified. The sensitivity of Doppler ultrasound for diagnosing BCS is reported as about 75–85% and specificity as 85–95%.
Blood screening tests include complete blood count (CBC), liver function tests (LFT), coagulation tests, LDH, and albumin as the basic evaluation. Screening tests for thrombophilia evaluation include JAK2 V617F mutation testing (PCR or allele-specific PCR), PNH screening (CD55/CD59 expression by flow cytometry), antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2GPI IgG/IgM), Factor V Leiden (APC resistance or direct genetic testing), prothrombin G20210A, and protein C/protein S/antithrombin activity.
Interpretation of blood counts for MPN screening is important. In polycythemia vera, hemoglobin >16.5 g/dL in men and >16.0 g/dL in women is one of the diagnostic criteria, but because of the dilutional effect of ascites due to BCS, dietary iron deficiency, and chronic bleeding, a positive JAK2 V617F suggests MPN (especially "masked PV") even if hemoglobin is within the normal range. A platelet count >450×10⁹/L suggests the possibility of ET. Peripheral blood smear and bone marrow examination (bone marrow biopsy and aspiration) are needed to confirm MPN.
When a myeloproliferative neoplasm is identified, regular follow-up for BCS is recommended. Conversely, a comprehensive thrombophilia evaluation must be completed in every patient diagnosed with BCS, and JAK2 V617F testing in particular should be performed as the top priority. Detection at a "latent stage," with only abnormal blood tests and no imaging abnormality, is also clinically meaningful and important in deciding whether to start prophylactic anticoagulation.
The core of diagnosing Budd-Chiari syndrome is confirming imaging or histopathological evidence of hepatic venous outflow obstruction (HVOO). Excluding conditions that mimic HVOO, such as primary heart disease, hepatic veno-occlusive disease (HVOD/SOS), and secondary flow abnormalities due to cirrhosis, is also an important part of the diagnosis.
Doppler ultrasound is the first-line imaging test for diagnosing BCS. It identifies monophasic or reversed hepatic vein waveforms, thrombus or web lesions, collateral formation, caudate lobe hypertrophy, and ascites. However, image quality may be limited by obesity, severe ascites, and bowel gas, in which case supplementation with CT or MRI is needed.
Abdominal CT (contrast-enhanced, triphasic) evaluates anatomical abnormalities of the hepatic veins and inferior vena cava in detail. Characteristic CT findings of BCS include ① non-opacification or thrombus of the hepatic veins, ② spider-web collaterals, ③ selective caudate lobe hypertrophy, ④ heterogeneous hepatic enhancement (nonuniform early enhancement: "flip-flop" pattern), and ⑤ thrombus or membranous lesions within the inferior vena cava. The "centripetal enhancement" pattern, in which the caudate lobe and liver periphery enhance early in the arterial phase and the center enhances in the portal phase, is characteristic of BCS.
MRI/MR angiography (MRA) is useful for evaluating vascular anatomy and the age of thrombus (acute vs. chronic) without radiation exposure. The age of a thrombus can be estimated from changes in its signal intensity on T1-weighted images. MRI is also excellent for evaluating the degree of liver fibrosis. Hepatic venography is now mainly used for planning before therapeutic procedures (TIPS, angioplasty), and its role as an invasive test solely for diagnosis has diminished.
In the diagnostic algorithm, when BCS is suspected in a patient with abnormal liver function and ascites: ① Doppler ultrasound → ② CT/MRI if abnormal or inconclusive → ③ confirmation of hepatic vein obstruction → ④ evaluation of cause (thrombophilia panel including JAK2 V617F, PNH, APS, FVL). Liver biopsy is generally performed to assess the degree of fibrosis, determine whether cirrhosis is present, and exclude HCC rather than to establish the diagnosis. Histologically, centrilobular congestion, centrilobular necrosis, sinusoidal dilation, and reverse fibrosis are characteristic of BCS.
Treatment of Budd-Chiari syndrome follows the principle of a "step-by-step approach." The treatment algorithm presented in the 2009 European Association for the Study of the Liver (EASL) guideline and its 2016 revision recommends a stepwise approach in the order ① anticoagulation → ② angioplasty/TIPS → ③ liver transplantation, evaluating the treatment response at each step before proceeding to the next.
Anticoagulation is the mainstay of treatment for all BCS patients. In the acute phase, treatment starts with low-molecular-weight heparin (LMWH) and is switched to a vitamin K antagonist (warfarin, target INR 2.0–3.0) or a direct oral anticoagulant (DOAC: rivaroxaban, apixaban). Efficacy data for DOACs in BCS are limited, but recent case series increasingly report fewer bleeding complications and similar efficacy compared with warfarin. Anticoagulation contributes to recovery of liver function by preventing rethrombosis and promoting collateral development.
Percutaneous angioplasty and stenting are tried first in patients with membranous obstruction of the inferior vena cava or focal vascular stenosis. Membranous obstruction is opened by balloon dilation, followed by stent placement to maintain long-term patency; with a high success rate and few complications, it is recommended as first-line treatment in MOVC patients. Catheter-directed thrombolysis (CDT) can be tried early for acute thrombus within 2–3 weeks of onset, but bleeding risk and the presence of underlying liver failure must be carefully considered.
Transjugular intrahepatic portosystemic shunt (TIPS) is the standard treatment when there is no response to anticoagulation or angioplasty or when symptoms worsen. Via the jugular vein, through the hepatic vein or inferior vena cava, a stent is placed into the intrahepatic portal vein, creating an artificial collateral channel between the portal and hepatic veins. TIPS bypasses the occluded hepatic veins to lower portal pressure, control ascites, and prevent variceal bleeding. With the use of PTFE-covered stents, 1-year patency has improved to more than 85%. Before TIPS, the Rotterdam prognostic score or BCS-TIPS prognostic index is used to predict prognosis and determine the appropriate timing of the procedure.
Portosystemic shunt surgery is considered when TIPS is technically impossible or has failed. Procedures include side-to-side portocaval anastomosis, mesocaval shunt, and splenorenal shunt. However, because surgical risk is high and it can increase technical difficulty during liver transplantation, its indications have greatly decreased with the development of TIPS and liver transplantation.
Liver transplantation is the last resort and curative treatment in patients with acute fulminant liver failure, progressive liver failure not responding to TIPS, and chronic BCS with complications of cirrhosis. Lifelong anticoagulation is essential after liver transplantation to prevent BCS recurrence. The 5-year survival after transplantation is reported as 70–75%. When there is an underlying MPN, use of a JAK inhibitor (ruxolitinib) before and after transplantation may be considered, and in PNH, eculizumab is effective in preventing thrombosis through complement inhibition. While awaiting liver transplantation, priority allocation using the MELD score and use of living donors (LDLT) are important.
The prognosis of Budd-Chiari syndrome has greatly improved over the past several decades with advances in treatment strategies. Before the 1980s, the 5-year survival after diagnosis was less than 50%, but with the introduction of TIPS, the widespread use of liver transplantation, and the systematization of anticoagulation, the 5-year survival has now improved to 70–80% or more.
Several scoring systems are used to predict prognosis. The Rotterdam prognostic score stratifies BCS-specific prognosis based on items within the Child-Pugh score (ascites, encephalopathy, prothrombin time, bilirubin, albumin). The BCS-TIPS Prognostic Index is a tool that helps decide on TIPS, using bilirubin, INR, and creatinine as variables. The MELD score (Model for End-Stage Liver Disease) is also widely used for liver transplant priority allocation and prediction of short-term mortality.
Factors that worsen prognosis include diagnostic delay, progression to cirrhosis, complicating hepatocellular carcinoma (HCC), recurrent thrombosis, and underlying malignancy. The incidence of HCC in BCS is about 2–4% per year, higher than in general cirrhosis patients, and BCS-specific carcinogenic mechanisms (chronic congestive injury, dysplastic change of regenerative nodules) have been proposed. Regular surveillance with abdominal ultrasound and AFP every 6 months is recommended for early detection of HCC.
Differences in prognosis by underlying cause are also important. In MPN-related BCS, improvements in thrombotic risk and symptom control have been reported with the use of a JAK inhibitor (ruxolitinib). In PNH-related BCS, eculizumab is effective in preventing complement-mediated thrombosis, and the BCS recurrence rate was greatly reduced in patients using eculizumab. In APS-related BCS, the intensity and duration of anticoagulation are important, and the risk of thrombosis recurrence is highest in triple-positive APS (lupus anticoagulant + anticardiolipin + anti-β2GPI all positive).
In patients who have undergone TIPS, the long-term prognosis depends on maintenance of stent patency and liver function. With the use of PTFE-covered stents, restenosis rates have fallen and the need for reintervention has decreased, and 5-year survival after TIPS is more than 70%. In liver transplant patients, 5-year survival after transplantation is 70–75%, and the presence of extrahepatic thrombosis before transplantation affects transplant success. Pediatric BCS is reported to have a better prognosis than adult BCS when appropriately treated.
Primary prevention of Budd-Chiari syndrome mainly aims at preventing thrombosis in high-risk groups with thrombophilia. Because BCS itself is a rare disease, active evaluation and prevention in specific groups carrying risk factors are more effective than applying prevention strategies to the entire general population.
Patients with myeloproliferative neoplasms (MPN) are a high-risk group for BCS, and in addition to regular liver function and abdominal ultrasound follow-up, antiplatelet therapy (low-dose aspirin) and anticoagulation when needed are recommended for thrombosis prevention. In MPN, controlling blood counts with phlebotomy or cytoreductive therapy (hydroxyurea, ruxolitinib) is key to lowering thrombotic risk. In MPN patients confirmed JAK2 V617F positive, BCS should be evaluated immediately when ascites or abnormal liver function of unknown cause develops.
In PNH patients, eculizumab administration markedly reduces complement-mediated thrombotic risk, and its preventive effect on intra-abdominal venous thrombosis including BCS has been demonstrated. Ravulizumab is a next-generation agent to eculizumab with improved convenience due to a longer dosing interval. In APS patients, hydroxychloroquine is known to lower thrombotic risk and reduce antiphospholipid antibody titers, and in high-risk APS (triple-positive), long-term warfarin anticoagulation is maintained.
To prevent recurrence after a first episode of BCS (secondary prevention), long-term anticoagulation is essential along with treatment of the underlying cause. Because the risk of thrombosis recurrence rises markedly when anticoagulation is stopped, the standard is to continue anticoagulation indefinitely unless the underlying cause has completely resolved. Anticoagulation is continued even after TIPS or liver transplantation, and Doppler ultrasound follow-up every 6 months is recommended to monitor for stent occlusion.
In terms of lifestyle, preventing dehydration (adequate fluid intake), avoiding prolonged immobility, and controlling excess weight are recommended as general principles of venous thrombosis prevention. Oral contraceptives raise venous thrombosis risk 3–4-fold due to their estrogen component and are therefore contraindicated in women with thrombophilia or a history of BCS. During pregnancy, anticoagulation with LMWH is recommended, and close cooperation of a multidisciplinary team (hematology, obstetrics and gynecology, gastroenterology) is needed. Blood tests, imaging surveillance, and anticoagulant monitoring through regular outpatient follow-up are key to the long-term management of BCS.